scispace - formally typeset
A

Andrew J. Fox

Researcher at Manchester Royal Infirmary

Publications -  97
Citations -  7911

Andrew J. Fox is an academic researcher from Manchester Royal Infirmary. The author has contributed to research in topics: Campylobacter jejuni & Multilocus sequence typing. The author has an hindex of 44, co-authored 96 publications receiving 7655 citations. Previous affiliations of Andrew J. Fox include Health Protection Agency & University College London.

Papers
More filters
Journal ArticleDOI

Antibody to the Gastric Campylobacter-like Organism (“Campylobacter Pyloridis”)—Clinical Correlations and Distribution in the Normal Population

TL;DR: There was little evidence to support an important pathological role for GCLO in disorders of the upper gastrointestinal tract, although the possibility that it may be a co-factor in the pathogenesis of gastric ulcer cannot be excluded.
Journal ArticleDOI

Molecular characterization of Campylobacter jejuni clones: a basis for epidemiologic investigation.

TL;DR: The data demonstrate that the clonal complex, as defined by MLST, is an epidemiologically relevant unit for both long and short-term investigations of C. jejuni epidemiology, and several clonal complexes exhibited associations with isolation source or particular cell-surface components.
Journal ArticleDOI

Meningococcal Serogroup C Conjugate Vaccine Is Immunogenic in Infancy and Primes for Memory

TL;DR: This meningococcal conjugate vaccine was well tolerated and immunogenic and induced immunologic memory in infants and produced fewer local reactions than concurrent routine immunizations.
Journal ArticleDOI

Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit.

TL;DR: The laboratory confirmation of meningococcal disease and characterization of Neisseria meningitidis isolates was improved considerably in England and Wales by the Meningococcal Reference Unit between epidemiological years 1993/94 and 2003/04 to meet the challenge of increasing numbers of cases of clinical disease and the requirement for enhanced surveillance.
Journal ArticleDOI

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

TL;DR: A novel genetically engineered vaccine containing six meningococcal class 1 (PorA) outer membrane proteins representing 80% of prevalent strains in the UK was safe and evoked encouraging immune responses in infants.